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Outward open conformation of a Major Facilitator
Superfamily multidrug/H+ antiporter provides
insights into switching mechanism
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Multidrug resistance (MDR) poses a major challenge to medicine. A principle cause of MDR
is through active efﬂux by MDR transporters situated in the bacterial membrane. Here we
present the crystal structure of the major facilitator superfamily (MFS) drug/H+ antiporter
MdfA from Escherichia coli in an outward open conformation. Comparison with the inward
facing (drug binding) state shows that, in addition to the expected change in relative
orientations of the N- and C-terminal lobes of the antiporter, the conformation of TM5 is
kinked and twisted. In vitro reconstitution experiments demonstrate the importance of
selected residues for transport and molecular dynamics simulations are used to gain insights
into antiporter switching. With the availability of structures of alternative conformational
states, we anticipate that MdfA will serve as a model system for understanding drug efﬂux in
MFS MDR antiporters.
DOI: 10.1038/s41467-018-06306-x OPEN
1 ZIK HALOmem, Kurt-Mothes-Straße 3, D-06120 Halle/Saale, Germany. 2 Institut für Biochemie und Biotechnologie, Charles-Tanford-Proteinzentrum,
Martin-Luther Universität Halle-Wittenberg, Kurt-Mothes-Straße 3a, D-06120 Halle/Saale, Germany. 3 Department of Cell Biology, Graduate School of
Medicine, Kyoto University, Konoe-cho, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan. 4 Agricultural Bioinformatics Research Unit, Graduate School of
Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan. 5 Advanced Science Research Center, Okayama
University, 1-1-1 Kita-ku, Tsushima-naka, Okayama 700-8530, Japan. 6 Department of Membrane Biochemistry, Okayama University Graduate School of
Medicine, Dentistry and Pharmaceutical Sciences, 1-1-1 Kita-ku, Tsushima-naka, Okayama 700-8530, Japan. 7 RIKEN, SPring-8 Center, 1-1-1 Kouto, Sayo-
cho, Sayo-gun, Hyogo 679-5148, Japan. 8 Structural Biology Research Center, Institute of Materials Structure Science, KEK/High Energy Accelerator
Research Organization, 1-1 Oho, Tsukuba, Ibaraki 305-0801, Japan. 9Present address: Institute of Virology, Hannover Medical School, Carl-Neuberg-Straße 1,
D-30625 Hannover, Germany. Correspondence and requests for materials should be addressed to M.T. (email: mikio.tanabe@kek.jp)
or to M.T.S. (email: stubbs@biochemtech.uni-halle.de)









Efﬂux transport of antibiotics and other potentially harmfulcompounds from the bacterial cytoplasm by multidrugresistance (MDR) transporters represents an increasing
challenge for the treatment of pathogenic bacterial infection1–3. A
large number of MDR transporters belong to the Major Facil-
itator Superfamily (MFS), found in both Gram-positive and
-negative organisms1,2. Typical MFS transporters possess 12
transmembrane helices (TMs) divided into two pseudo-
symmetrical 6TM N- and C-terminal lobes. Changes in relative
orientation of the two lobes within the plane of the bilayer (the
rocker-switch mechanism4) allow alternating access to the cyto-
plasmic and extracellular/periplasmic sides of the membrane,
facilitating directed transport of substrates across the membrane,
with the transporter cycling between outward open (Oo), inward
open (Io) and intermediary occluded states5–7. Despite progress in
structural determinations of these states for uniporter and sym-
porter MFS transporters, few such data are available for
antiporters.
MdfA, an MFS-MDR transporter from E. coli with homologs in
many pathogenic bacteria, is an extensively characterized drug/H+
antiporter8. It transports lipophilic, cationic, and neutral sub-
strates, in each case driven by the proton motive force9,10. Two
acidic residues within TM1, Glu26TM1 and Asp34TM1, have been
implicated in proton (H+) and substrate transport coupling11–13,
and it has been proposed that changes in their protonation could
lead to local structural changes within the binding pocket upon
H+/substrate binding11. The recently reported structure of
chloramphenicol-bound MdfA in an inward facing (If) con-
formation14 reveals the antibiotic bound in the immediate vicinity
of Asp34TM1, in line with earlier biochemical data12,13.
In order to gain a complete picture of the efﬂux mechanism,
however, structural data for alternative states are required. Here we
report the crystal structure of MdfA in the Oo state and identify
conformational changes that accompany transitions between the If
and Oo states. With the availability of structures of alternative
conformational states, we anticipate that MdfA will serve as a model
system for understanding drug efﬂux in MFS MDR antiporters.
Results
Overall structure of MdfA in the outward open (Oo) state. The
crystal structure of Fab-bound MdfA presented here reveals the
transporter in the outward open (Oo) state, with the N- and C-
lobes approaching each other closely at the intracellular face of
the transporter (Fig. 1). The N-terminus of TM5 juxtaposes the
C-termini of TM8 and TM10 and the N-terminus of TM11
nestles between the C-termini of TM2 and TM4. Access to the
transporter cavity from the cytoplasmic face is sealed off by
formation of a hydrophobic plug through intercalation of side-
chains from each of these helices centered around Phe340TM10
(Fig. 2). These contacts are supported by mutually favorable
interactions between the side chain of Arg336TM10 and the C-
terminal dipole of TM4, and Asp77TM2 and the N-terminal
dipole of TM11. Asp77TM2 (from conserved motif A) is in
addition part of an electrostatic cluster involving Arg81TM3 and
Glu132TM5, with an adjacent cluster including Arg78TM2 and
residues of the intermediate loop (Arg198α6–7) and helix
(Asp211α6–7).
In the ligand bound If state, in which the two lobes rotate
largely as rigid bodies by 33.5° about an axis parallel to the plane
of the membrane bilayer, these multiple interactions are replaced
by predominantly hydrophobic contacts between the periplasmic
halves of TMs 1, 2, and 5 of the N-terminal domain and TMs 7, 8,
and 11 of the C-terminal domain. This is effected by a sliding of
TM11 along TM2 and a signiﬁcant rearrangement of TM5 (see
below), closing the transporter cavity to the periplasm. The drug
binding pocket observed in the If state is disrupted in the Oo state
through displacement of Ala150TM5 and Leu151TM5 (see below)
as well as lateral movement of C-terminal domain residues from
TMs 7 and 8 (Supplementary Fig. 1).
MdfA helix TM5 is kinked and twisted in the Oo state.
Superposition of the individual domains of MdfA in the If and
Oo conformations reveals signiﬁcant deviations in the N-terminal













































Fig. 1 Overall structure of MdfA in the outward open (Oo) and inward facing (If) states. a The transporter in the Oo conformation (this work); bMdfA in the
ligand-bound If state (ref. 14). The N- (white/gray) and C-terminal (yellow) six transmembrane helical domains are shown in ribbon representation, with
transmembrane helices (TMs) numbered. Note the difference in relative orientation of the two domains by 33.5°. TM5, whose conformation differs
between the two states, is shown in green (Oo) or orange (If); the TM1–TM2 termini are in corresponding light colors. The position of chloramphenicol
bound in the If state is depicted using blue sticks
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found in TM5, which ends in the antiporter motif C
153AlaProXaaXaaGlyPro158 that is absent in symporters and
uniporters15. Whereas TM5 in the If structure adopts an α-helical
conformation of almost ideal geometry up to motif C, residues
136 to 153 in the Oo structure exhibit a profound 15° kink,
accompanied by a ca. 45° clockwise twist parallel to the helix axis
that terminates with the two-proline-containing motif C (Fig. 3;
Supplementary Fig. 3; Supplementary Movie). This results in a
repositioning of the hydrophobic side chains Ile142TM5,
Leu145TM5, Met146TM5, and Val149TM5 with respect to the N-
terminal domain core. Leu145TM5, which in the If conformation
associates with the N-terminal domain, engages instead with
residues of the C-terminal domain in the Oo state. The carbox-
amide of conserved Asn148TM5 is removed from a (presumably
hydrophobic) membrane exposed location in the If state to form















































Fig. 2 Cytoplasmic and periplasmic faces of MdfA in the outward open conformation. a The cytoplasmic entrance to the ligand-binding pocket is closed in
the Oo conformation by numerous interactions between the N- and C-lobes (view obtained by rotating Fig. 1 90° about a horizontal x-axis). The N-terminus
of TM5 juxtaposes the C-termini of TM8 and TM10, and the N-terminus of TM11 nestles between the C-termini of TM2 and TM4. Hydrophobic sidechains
from each of these helices pack against each other to form a hydrophobic plug that seals off access to the transporter cavity from the cytoplasmic face,
supported by additional mutually favorable electrostatic interactions. b View from the periplasmic face (following a 180° rotation about a horizontal x-axis),
demonstrating the deep cavity between the two domains in the outward open conformation. Dotted line denotes approximate boundary delineated by the
bacterial membrane outer leaﬂet head groups
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06306-x ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:4005 | DOI: 10.1038/s41467-018-06306-x |www.nature.com/naturecommunications 3
chain carbonyl of Ile269TM8 in the Oo conformation. The largest
deviation in TM5 is found at residue Met146TM5, the side chain
of which rests against the aromatic moiety of Tyr127TM4 in the
present structure. In turn, the side chain hydroxyl of Tyr127TM4
is found within hydrogen bonding distance (2.5 Å) of the car-
boxylate of Glu26TM1 in the Oo structure. Crucially, the space
occupied by the Tyr127TM4 side chain in the Oo state is in the If
structure replaced by that of Met146TM5.
Rearrangements in the N-terminal domain hydrophobic core.
Also of note are small yet signiﬁcant changes in the region
Leu41TM1–Val54TM2, which runs from the C-terminus of TM1
and the N-terminus of TM2 (Supplementary Fig. 4). The side
chains of residues Val43TM1, Tyr47TM1, and Trp53TM2 form part
of a hydrophobic cluster near the periplasmic face of MdfA that
includes Met40TM1, Ile105TM4, and Phe108TM4 from TM4, and
Trp170TM6 and Phe174TM6 at the N-terminus of TM6. This
cluster, which juxtaposes the buried guanidinium moiety of
Arg112TM4 that is absolutely conserved among MFS homologs
(motif B), exhibits a small but signiﬁcant expansion in the present
structure compared to that in the If conformation. While the
structural differences may appear to be small, we note that
the transporter MdfA is stabilized by ligand binding14,16, so that
the transporter in the unbound Io state could well differ from the
ligand bound MdfA If structures presented by Heng et al.14,17.
In order to test the effect of amino acid substitutions on
chloramphenicol transport experimentally, MdfA and its variants
were reconstituted in proteoliposomes following procedures
described for the chloroquine resistance transporter from
Plasmodium falciparum18 (Fig. 4). Puriﬁed reconstituted wild-
type MdfA was able to transport 50 pmol chloramphenicol
(per mg protein per minute), which compares favorably with the
3 pmol mg−1 min−1 determined using crude membrane prepara-
tions19, whereas transport proved unaffected by mutation of
Glu26TM1 to Gln, suggesting that the charge state of this residue
is not crucial for chloramphenicol transport. The variants
Tyr127TM4Phe, Met146TM5Ala, and Trp170TM6Ala of the
hydrophobic core all showed signiﬁcant reductions in transport
in the presence of a pH gradient. As expected, chloramphenicol
transport was low in the absence of ΔpH, arising from downhill
transport due to the initial inﬁnite substrate gradient.
Molecular dynamics simulations. To gain further insights into
the transport cycle, molecular dynamics (MD) simulations were
performed with all possible combinations of Glu26TM1 and
Asp34TM1 protonation states, starting from either the Oo struc-
ture without Fab or the If structure without chloramphenicol.
Initial trials with the present structure assuming both acidic
residues to be deprotonated [Oo(E26−/D34−)] indicated that the
overall structure remained unchanged during the MD simulation.
The C-terminal lobe is more rigid than the N-terminal lobe, and
the cytoplasmic halves of the TM helices (relative to the center of
the lipid bilayer) showed smaller root mean square deviation
(RMSD) values than those of the periplasmic halves of the TM
helices (Supplementary Table 1)—despite the fact that the Fab
binds to the cytoplasmic face of MdfA. We therefore conclude
that the outward-open conformation of MdfA is little affected by
Fab binding (corroborated by low-resolution data from crystals of
MdfA alone20) and is stably maintained in a solvated membrane
environment.
To monitor the degree of conformational change, two distances
were used to describe the opening and closing of the periplasmic
and cytoplasmic sides of the transporter (d1 and d2 respectively)
(Fig. 5). Starting from the Oo state, the largest divergence from
the crystal structure was observed when Asp34TM1 was proto-
nated [Oo(E26−/D34p) and Oo(E26p/D34p)], resulting in small
values of d1 and d2. This state corresponds to an occluded












































































Fig. 3 The Oo and If conformations differ by local twisting of TM5. a In the Oo state, TM5 (green) in the N-terminal domain is partially distorted, resulting in
Cα displacements compared to the If state of up to 2.9 Å (Met146TM5). The side chain of Met146TM5 rests against the phenolic side chain of Tyr127TM4,
whose hydroxyl moiety is ca. 2.5 Å from the side chain carboxylate group of Glu26TM1. b TM5 adopts an almost ideal α-helical conformation in the If state
through displacement of the Tyr127TM4 side chain by that of Met146TM5. TM5 straightens, rotating around its axis such that its hydrophobic side chains
can engage/disengage the C-terminal domain. c Electron density for TM5 in the Oo conformation, superimposed with coordinates of the ﬁnal (green) and
initial (orange) models. See also Supplementary Fig. 3 and Supplementary Movie
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are closed. Analysis of the free energy landscape for this transition
(Supplementary Fig. 5a) indicates that upon protonation of
Asp34TM1, the Oo state is much less stable than the occluded
state, suggesting that the transition occurs rapidly and is in effect
irreversible. During the simulations, the hydrogen bond between
Glu26TM1 and Tyr127TM4 was for the most part maintained,
although the carboxylate at times also hydrogen bonded to
Tyr30TM1 (Supplementary Fig. 6).
In the occluded state adopted following Asp34TM5 protonation,
the acidic side chain juxtaposes an internal cavity bounded by the
conserved residues Tyr257TM8, Gln261TM8 as well as the
hydrophobic side chains of Ile239TM7 and Phe265TM8; this cavity
is also observed in the If crystal structure (Supplementary Fig. 7).
TM5 is straighter than in the Oo and If structures, although it
adopts a twisted conformation as in the Oo structure.
Starting from the If crystal structure after removal of the ligand
and replacement of Arg131TM4 by the wild-type Gln, a similar
occluded state was obtained during the MD run If(E26−/D34p).
In contrast to the transition from the Oo state, however, the If and
the occluded states are in a ﬂat free-energy well (Supplementary
Fig. 5b), suggesting that these two states can co-exist when
Asp34TM5 is protonated and that the transition between the If
state and the occluded state is reversible. As we observed only a
one-way transition from the If state to the occluded state in the
1 μs MD simulation, the transition must be slow, presumably due
to the complex and rugged nature of the original multi-
dimensional energy surface. During this simulation, TM5 twisting
was observed due to the close approach of the cytoplasmic halves
of TM5 and TM8 (i.e. decreasing d2), following accommodation
of Leu151TM5 in the space between Leu268TM8 and Ile269TM8
(Supplementary Fig. 7). During the simulations where Glu26TM1
was protonated [If(E26p/D34−) and If(E26p/D34p)], Tyr127TM4
moved toward Glu26TM1 (Supplementary Fig. 6).
Discussion
The structure of MdfA presented here reveals features of the Oo
conformation and allows comparison with the previously deter-
mined ligand bound If state14. Going from the If to the Oo state,
the N- and C-terminal domains of the transporter reorient in the
membrane largely as rigid bodies, with the exception of three
regions: (i) transmembrane helix TM5 kinks and twists, (ii) the
periplasm-proximal hydrophobic core of the N-terminal domain
reorganizes, and (iii) a cytoplasmic loop of the C-terminal
domain rearranges to accommodate closure of the cytoplasmic
entrance (see Supplementary Movie). The twisting of the helix in
the Oo conformation appears to be prevented from transiting to a
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Fig. 4 Chloramphenicol transport by MdfA reconstituted in proteoliposomes. a Chloramphenicol transport into reconstituted proteoliposomes is
dependent upon the presence of MdfA and a pH gradient. b Time course for uptake using reconstituted MdfA. In the absence of a pH gradient (open
circles), downhill-like transport (with the substrate gradient) occurs rapidly due to the small volume of the proteoliposomes. In the presence of a pH
gradient, however, chloramphenicol uptake (ﬁlled circles) involves at least three phases: following a rapid initial downhill transport phase (not visible),
uphill accumulation of the substrate in the liposomal lumen against the concentration gradient takes place at the expense of proton export (II). Within a
few minutes, the situation is reversed due to lumen acidiﬁcation, leading to chloramphenicol efﬂux (phase III). Crucially, collapse of the pH gradient through
administration of the H+-ionophore CCCP (open squares) results in rapid chloramphenicol efﬂux (downhill transport) until the luminal concentration
reaches that observed in the absence of a pH gradient. c, d Schematic diagram illustrating the phases of chloramphenicol (CLM) uptake in the reconstituted
system. e Uptake by proteoliposomes containing puriﬁed MdfA variants in the presence (closed bars) and absence (open bars) of a pH gradient at 1 min.
Data are mean values ± s.d., n= 3
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Tyr127TM4 and Met146TM5 side chains, with the aromatic side
chain hydroxyl of Tyr127TM4 held in place by a hydrogen bond to
Glu26TM1. Our reconstitution experiments demonstrate the
importance of Tyr127TM4 and Met146TM5 for transport, and
suggest that the charge state of Glu26TM1 is of little signiﬁcance
for chloramphenicol transport in the presence of a pH gradient,
which is consistent with previous results19. It should be noted
that, strictly speaking, the conclusions presented here apply only
to chloramphenicol transport (for which structural data of the If
form are available); whereas we expect them to be generally valid
for other neutral MdfA substrates, the situation may differ for
other substrates.
To gain further insights into the transport process, we per-
formed MD simulations involving different protonation states of
the two acidic residues identiﬁed previously as being important in
in vivo studies11,16,21, Asp34TM1 and Glu26TM1. Within the
timescale of our simulations, protonation of Asp34TM1 through
exposure to the low pH periplasmic space leads to an occluded
state in which the acidic side chain becomes enclosed in an
internal cavity that recapitulates its environment in the If con-
formation. TM5 continues to be twisted in this occluded state and
the Glu26TM1–Tyr127TM4 hydrogen bond remains intact,
although the charge state of Glu26TM1 does not appear to play a
role in this. Nevertheless, previous in vivo studies have shown
that Glu26TM1 is critical for the transport of cationic sub-
strates11,16, so that the situation may be different for cationic and
lipophilic substrates, in which the initial If state assumed here
might not apply.
MD simulations also demonstrate that an occluded state and a
twisted TM5 conformation can be obtained starting from the If
state. The fact that the transporter is stabilized by ligand bind-
ing14,16 however means that the If structures presented by Heng
et al.14,17 might not provide an accurate representation of MdfA
in the unbound Io state (moreover, these ligand-bound structures
were obtained using a mutated variant Gln131TM4Arg, which has
recently been reported to be transport inactive22,23). Thus TM5
untwisting might occur on going from the occluded to the Io state,
or upon ligand binding to form the If state.
Recent structure determinations of other transporters5–7 indi-
cate that individual helices within each domain can exhibit
signiﬁcant variability upon conformation switching. For MdfA,
the existence of structurally underdetermined Io and intermediate
occluded states (whereby ligand bound and unbound occluded
states are likely to be different) thus precludes a detailed
description of the complete transport cycle. Nevertheless, the
combination of data presented here suggests an important role for
the interaction between Glu26TM1 and Tyr127TM4. We note that
through their common location on helix TM4, the orientation of
the Tyr127TM4 side chain could couple with the environment of
the motif B Arg112TM4 side chain. The buried guanidinium
moiety is involved in an elaborate hydrogen bonding network
involving the even more buried Gln115TM4, the carbonyl carbon
of Gly32TM1, and (via a solvent molecule identiﬁed in the high-
resolution structure14) Asn33TM1 and Asp34TM1. Residues
Arg112TM4, Asp34TM1, Gln115TM4, and Gly32TM1 have all been
shown to be important for MdfA action11,14,16,19,24, and a role of
the surrounding hydrophobic cluster is conﬁrmed by the dele-
terious effect on chloramphenicol transport of the Trp170TM6Ala
mutation. Changes in the chemical environment of Asp34TM1
(e.g. by ligand binding or changes in protonation) could therefore
lead to the observed reorganization of the hydrophobic cluster
immediately adjacent to Arg112TM4. In turn, communication of
this change through TM4 could inﬂuence the orientation of the
Tyr127TM4 side chain, dictating the position of that of
Met146TM5 and thereby the degree of TM5 twist. Releasing the
twist of TM5 from the Oo to the If conformation would result in a
repositioning of the hydrophobic side chains Ile142TM5,
Leu145TM5, Met146TM5, and Val149TM5 with respect to the N-
terminal domain core, allowing Leu145TM5 to dissociate from the
N-terminal domain to engage the C-terminal domain.
Support is provided by MdfA rescue mutants. Selection for
drug transport rescue in cells harboring the otherwise inactive
TM1 variants Glu26TM1Thr/Asp34TM1Met and Glu26TM1Thr
resulted in the detection of mutants containing the acidic side
chains Ala150TM5Glu and Val335TM10Glu11,25. These residues
would be well positioned to make hydrogen bonds to Tyr127TM4
in the outward open structure (Supplementary Fig. 8). Recent
thermodynamic calculations and molecular dynamic simulations
have led in principle to similar conclusions for the L-fucose/H+
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Fig. 5 Conformational distributions of MdfA obtained following MD simulations. Starting from each initial conformation (Oo vs. If) and Glu26/Asp34
protonation state, the conformational distributions of the MD simulations were calculated as a function of d1 and d2 (d1: minimum distance between Cα
atoms of residues 156–165 (TM5) and those of residues 253–262 (TM8); d2: minimum distance between Cα atoms of residues 139–148 (TM5) and those
of residues 270–279 (TM8)). Cyan squares indicate the corresponding distances in the initial conformations (Oo: this study; If PDB 4ZOW), and the blue
circles indicate the position of the peak in the plot for Oo(E26−/D34p)
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proposed that protonation of FucP Glu135TM4 in TM4 allows
surmounting of a ca. 2 kcal mol−1 energy barrier between the
inward and outward open states. An intermediate state in which
TM11 is distorted is postulated, although a causative link between
Glu135TM4 (de)protonation and TM11 distortion has not been
described. Inspection of the FucP structure27 suggests that
Glu135TM4 could form a hydrogen bond with Tyr365TM10 of C-
terminal domain TM10 (Supplementary Fig. 8). Interestingly, C-
terminal domain TM11 is the counterpart of TM5 in the
(inverted topology) N-terminal domain28, reﬂecting the pseudo-
symmetry of the two domains, so that the antiporter MdfA and
symporter FucP might be thought of as examples of repeat
swapping to yield similar transport mechanisms.
The presence of the MFS-antiporter motif C would appear to
be central to transporter switching—restricting the twist of TM5
to a small localized helical segment to facilitate relative rotation of
the two domains, and transmitting these perturbations to an
adjacent pliable hydrophobic cluster. As other structurally well-
characterized antiporter families (such as the amino acid/poly-
amine/organocation (APC) transporter superfamily29 and cation/
H+ antiporter family30) have been shown to utilize other
mechanisms, this may be a property speciﬁc to MFS-antiporters.
The Oo structure presented here could serve as a template for the
design of novel MFS inhibitors that are able to access their target
directly from the bacterial exterior.
Methods
Crystal structure solution. Isolation of Fab fragments that recognize native
conformations of MdfA in proteoliposomes has been described elsewhere31. Co-
crystals of MdfA in complex with Fab fragments grew in the lipidic cubic phase and
diffracted to 3.4 Å resolution20,31. Diffraction data were collected at 100 K at a
wavelength of 1.0 Å on the SLS beamline PXI (X06SA) using the 16M Eiger
detector. In order to resolve the very long c-axis (929 Å), the crystal was mounted
so that the rotation axis was ca. 30° to the crystallographic c-axis. The synchrotron
beam (with beam size increased from 10 to 100 µm) was defocused from the crystal
to the detector. Data sets (180° in 0.1° steps) were processed using the program
XDS32. The crystal belongs to the space group P6122 with one complex in the
asymmetric unit. Phases were determined by molecular replacement with PHASER
MR33 using the separated N- and C-lobes of MdfA in the inward open con-
formation (PDBID: 4ZP0)14 and an Fab fragment (PDBID:1IBG)34 as individual
search models. The replacement model was rebuilt manually using COOT35 and
reﬁned using PHENIX36 with TLS reﬁnement (three groups per polypeptide chain)
to an Rfree value of 28.3%. The ﬁnal model consists of MdfA residues
Gln14–Lys400, Fab heavy chain residues Leu4–Pro216, and Fab light chain resi-
dues Asp1–Arg211, as well as one sulfate ion. Ramachandran analysis demon-
strates that 94.4% of the residues are in the favorable regions and 5.5% in the
allowed regions. One residue (Ser65 in the Fab fragment heavy chain) was in the
outlier regions. Atoms for difference density corresponding to solvent molecules,
lipids, and/or detergents were not added to the model in accordance with the low
resolution of the data. The Fab binds to the cytoplasmic side of MdfA, where it may
stabilize the outward open state and enhances crystal contacts20. Data collection
and reﬁnement statistics are given in Table 1. RMSDs in Cα in positions between
Oo and If states (Supplementary Fig. 2) were calculated as a function of residue
number after separate superposition of the N- and C-terminal domains using the
programme LSQKAB from the CCP4 suite37. The kink of α-helix TM5 was cal-
culated using Kink Finder38. Figures and movies were prepared using PyMOL
(Schrödinger, LLC).
Reconstitution of MdfA. MdfA mutants were generated using a PCR site-directed
mutagenesis kit (Agilent) with the primers listed in the Supplementary Table 2, and
puriﬁed as for wild-type MdfA. Forty micrograms of puriﬁed wild type or mutant
MdfA was mixed with 500 μg of azolectin liposomes (Sigma type IIS), frozen at 193
K for at least 10 min18. The mixture was thawed quickly by holding the sample tube
in the hand and diluted 60-fold with reconstitution buffer containing 20 mM MES-
NaOH (pH 6.0), 0.1 M sodium chloride, 5 mM magnesium chloride. Reconstituted
proteoliposomes were pelleted by centrifugation at 200,000 × g at 277 K for 1 h, and
suspended in 0.2 mL of same buffer.
Transport assay. The transport assay mixture (0.2 mL) containing 20 mM MOPS-
Tris (pH 7.5) or 20 mM MES-NaOH (pH 6.0), 0.1 M sodium chloride, 5 mM
magnesium chloride, and 2 μM [ring-3,5 3H] chloramphenicol (0.5 MBq μmol−1,
PerkinElmer) was incubated at 300 K for 3 min. Proteoliposomes containing MdfA
(0.5 μg protein per assay) (or liposomes as control) were added to the mixture to
initiate transport, and incubated for a further 1 min. Aliquots (130 μL) were taken
and centrifuged through a Sephadex G-50 (ﬁne) spin column at 760 × g for 2 min.
Radioactivity in the eluate was counted using a liquid scintillation counter (Per-
kinElmer). As a control, the ionophore carbonyl cyanide m-chlorophenyl hydra-
zone (CCCP) was added to the assay (ﬁnal concentration 1 μM) after 1 min to
collapse the pH gradient. Bovine serum albumin was used as a protein con-
centration standard39.
MD simulations. Initial coordinates of MdfA in the Oo conformation were taken
from those of the crystal structure of the MdfA–Fab complex. N- and C-terminal
MdfA residues were capped with acetyl and N-methyl groups, respectively. All
histidine residues were protonated on the Nδ1 atom. All acidic residues (excluding
Glu26TM5 and Asp34TM5) and all basic residues were deprotonated and proto-
nated, respectively (see Supplementary Table 3). Glu26TM5 was protonated in the
initial structure of the Oo(E26p/D34−) and Oo(E26p/D34p) simulation runs and
Asp34TM5 was protonated for the Oo(E26−/D34p) and Oo(E26p/D34p) simulation
runs. After ﬁlling the large cavity on the periplasmic side of the protein with water
molecules to prevent placement of lipid molecules there, the structure was
embedded in a lipid bilayer and solvated with water and ions using CHARMM-
GUI40. The orientation of MdfA relative to the lipid bilayer was determined
analogously to that of MdfA in the If state (PDB ID: 4ZP0) as deposited in the
Orientations of Proteins in Membranes (OPM) database41 by alignment of the Cα
atoms of residues 203–400. The rectangular simulation system generated by
CHARMM-GUI (90.76 Å × 90.76 Å × 96.98 Å) was subjected to periodic boundary
conditions. The system was composed of one protein, 223 1-palmitoyl-2-oleoyl-sn-
phosphatidylethanolamine (POPE), 40 or 41 K+, 44 or 45 Cl–, and about 14,000
water molecules. The CHARMM36 force-ﬁeld parameters42,43 were used for
protein, lipid, and ions, and the TIP3P model44 was used for water. Initial coor-
dinates for the simulations starting from the If conformation were generated in a
similar manner. Here, the coordinates of the chloramphenicol-bound, If form of
MdfA (PDB ID: 4ZOW) was used after the ligand coordinates were removed and
Arg131 was replaced with the wild-type Gln residue. The system size was 92.01 Å ×
92.01 Å × 98.11 Å and was composed of 233 POPE, 41 or 42 K+, 47 or 48 Cl−, and
about 14,700 water molecules.
After energy minimization and equilibration, a production MD run was
performed for 1.6 μs (starting from the Oo conformation) or 1.0 μs (starting from
the If conformation). During the simulation, the temperature was kept at 303.15 K
using the Nosé–Hoover thermostat45,46, and the pressure was kept at 1.0 × 105 Pa
using the semi-isotropic Parrilello-Rahman barostat47,48. Bond lengths involving
hydrogen atoms were constrained using the LINCS algorithm49,50 to allow the use
of a large time step (2 fs). Electrostatic interactions were calculated with the particle
mesh Ewald method51,52. All MD simulations were performed with Gromacs 5.0.5
(ref. 53), with coordinates recorded every 10 ps.
Time evolutions of RMSDs in the Oo(E26–/D34p) and If(E26–/D34p) MD runs
were calculated using their respective initial and ﬁnal structures as reference
(Supplementary Fig. 9). The average values of the RMSDs from the ﬁnal structures





a, b, c (Å) 73.26, 73.26, 927.92
α, β, γ (°) 90.00, 90.00, 120.00
Resolution (Å) 49–3.4 (3.61–3.4)a
Rsym or Rmerge 25.4 (166.9)
I /σI 11.57 (1.59)













Bond lengths (Å) 0.003
Bond angles (°) 0.596
aValues in parentheses are for highest-resolution shell
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of the Oo(E26–/D34p) and If(E26–/D34p) runs calculated for the last 2.7μs
trajectory of the Oo(E26–/D34p) MD run were 1.24 ± 0.14 and 1.21 ± 0.08 Å,
respectively. Corresponding values calculated for the last 0.5μs trajectory of the
If(E26–/D34p) MD run were 1.48 ± 0.16 and 1.23 ± 0.26 Å, respectively. Thus the
two simulations converged to similar states.
Data availability
Data supporting the ﬁndings of this manuscript are available from the corresponding
authors upon reasonable request. Coordinates of the MdfA–Fab complex have been
deposited in the Protein Data Bank under the accession number 6GV1 (https://doi.org/
10.2210/pdb6GV1/pdb).
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